J
Jeffrey A. Knauf
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 85
Citations - 10769
Jeffrey A. Knauf is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Thyroid cancer & Thyroid. The author has an hindex of 45, co-authored 75 publications receiving 9589 citations. Previous affiliations of Jeffrey A. Knauf include University of Cincinnati & Los Alamos National Laboratory.
Papers
More filters
Journal Article
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Edna Teruko Kimura,Marina N. Nikiforova,Zhaowen Zhu,Jeffrey A. Knauf,Yuri E. Nikiforov,James A. Fagin +5 more
TL;DR: It is shown that a somatic mutation of BRAF, V599E, is the most common genetic change in PTCs, and represents a unique paradigm of human tumorigenesis through mutation of three signaling effectors lying in tandem.
Journal ArticleDOI
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
Marina N. Nikiforova,Edna Teruko Kimura,Manoj Gandhi,Paul W. Biddinger,Jeffrey A. Knauf,Fulvio Basolo,Zhaowen Zhu,Riccardo Giannini,Giuliana Salvatore,Alfredo Fusco,Massimo Santoro,James A. Fagin,Yuri E. Nikiforov +12 more
TL;DR: BRAF mutations are associated with distinct phenotypical and biological properties of papillary carcinomas and may participate in progression to poorly differentiated and anaplastic carcinomas.
Journal ArticleDOI
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Iñigo Landa,Tihana Ibrahimpasic,Laura Boucai,Rileen Sinha,Jeffrey A. Knauf,Ronak Shah,Snjezana Dogan,Julio C. Ricarte-Filho,Gnana P. Krishnamoorthy,Bin Xu,Nikolaus Schultz,Michael F. Berger,Chris Sander,Barry S. Taylor,Ronald Ghossein,Ian Ganly,James A. Fagin +16 more
TL;DR: These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance.
Journal ArticleDOI
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
Rebecca E. Schweppe,Joshua P. Klopper,Christopher Korch,Umarani Pugazhenthi,Miriam Benezra,Jeffrey A. Knauf,James A. Fagin,Laura A. Marlow,John A. Copland,Robert C. Smallridge,Bryan R. Haugen +10 more
TL;DR: The results emphasize the importance of cell line integrity, and provide the short tandem repeat profiles for a panel of thyroid cancer cell lines that can be used as a reference for comparison of cell lines from other laboratories.
Journal ArticleDOI
Mutational Profile Of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA and AKT1
Julio C. Ricarte-Filho,Mabel Ryder,Dhananjay Chitale,Michael Rivera,Adriana Heguy,Marc Ladanyi,Manickam Janakiraman,David B. Solit,Jeffrey A. Knauf,R. Michael Tuttle,Ronald Ghossein,James A. Fagin +11 more
TL;DR: An assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease encompassing 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes was designed to obtain comprehensive genetic information on advanced thyroid cancers.